Who Optimizes SG&A Costs Better? TG Therapeutics, Inc. or HUTCHMED (China) Limited

SG&A Cost Management: TG Therapeutics vs. HUTCHMED

__timestampHUTCHMED (China) LimitedTG Therapeutics, Inc.
Wednesday, January 1, 20142668400024518692
Thursday, January 1, 20152982900019886580
Friday, January 1, 20163957800012631689
Sunday, January 1, 20174327700021977998
Monday, January 1, 20184864500020759000
Tuesday, January 1, 20195293400020838000
Wednesday, January 1, 202061349000121812000
Friday, January 1, 2021127125000152137000
Saturday, January 1, 202213610600083231000
Sunday, January 1, 2023133175999122706000
Loading chart...

Unleashing the power of data

Optimizing SG&A Costs: A Tale of Two Companies

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, TG Therapeutics, Inc. and HUTCHMED (China) Limited have shown distinct strategies in optimizing these costs. From 2014 to 2023, HUTCHMED's SG&A expenses grew by approximately 400%, peaking in 2022. Meanwhile, TG Therapeutics saw a more volatile trend, with a significant spike in 2021, where expenses surged by over 600% compared to 2016. Despite these fluctuations, both companies have demonstrated resilience, with TG Therapeutics showing a notable reduction in 2022. This data highlights the dynamic nature of cost management in the pharmaceutical industry, where strategic financial planning can significantly impact a company's bottom line. As these companies continue to innovate, their ability to control SG&A expenses will remain a key factor in their financial health.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025